Jaime Deville
Pediatric Infectious Diseases · Los Angeles, CANPI 1750301503
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,325 of the $15,580 with a category attached, or 85.5%. GSK accounts for 73.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $12,707 and has fallen 79.8% since, to $2,570 in 2025. Among pediatric infectious diseases clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $677.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Merck$3K
- Astellas Pharma US Inc$1K
- Viiv Healthcare Company$154
- Gilead$95
Across 561 payments — averaging $3292.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$472K
- Gilead$462K
- Pfizer$317K
- Viiv Healthcare Company$97K
- Astellas US Technologies$95K
- La Jolla Pharmaceutical Company$73K
- plus $331K from 9 others
What the payments were for
- Consulting fees$13,32586%
- Travel & lodging$1,3759%
- Food & beverage$8806%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $11,469 |
| Merck | 5 | $2,625 |
| Astellas Pharma US Inc | 4 | $1,239 |
| Viiv Healthcare Company | 2 | $154 |
| Gilead | 3 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,580 in reported general payments places this provider in the 90th percentile of 83 pediatric infectious diseases providers in California.
See all pediatric infectious diseases providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $38,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $95 | $38,96711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 83 pediatric infectious diseases providers in California.
Other pediatric infectious diseases in Los Angeles
- Lashonda SpencerLos Angeles$123K
- Michael NeelyLos Angeles$14K
- Annabelle de St MauriceLos Angeles$5K
- James CherryLos Angeles$3K
- Mikhaela CieloLos Angeles$336
- Mark SalzmanLos Angeles$186
- Paul KrogstadLos Angeles$154
- Jennifer RatheLos Angeles$125
- Leila PoschLos Angeles$124
- Grace AldrovandiLos Angeles$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.